61 results about "CCR4" patented technology

A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.

The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.

The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 4 (CCR4) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR4 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.

A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.

A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Chemokine receptor CCR4 and its ligands CCL1 7 and CCL22 are used as markers for the identification and / or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL 17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL 17 and CCL22 provide anti-cancer agents.

The invention discloses a tumor immunization method combining with chimeric antigen T cells targeting at PD-1 (programmed cell death protein 1) and EGFR (epidermal growth factor receptor) and also discloses a plasmid vector for implementing the method. In combination with fourth-generation CAR-T (chimeric antigen receptor T) cells targeting at PD-1 and EGFR, a lentiviral vector is used as a CAR-T vector basic structure, and truncated EGFR antibody is selected as a CAR core to give tumor targeted enrichment to play, tumor-killing effect is given to play in conformity with overexpressed immune checkpoint inhibitor PD-1 monoclonal antibody; by constructing the fourth-generation CAR-T vector for co-expressing various regulatory factors such as IL21, CCR4 and Bcl2, the killing, homing and persistent proliferating abilities of CAR-T cells are improved. EP-CAR T (esophageal papilloma chimeric antigen receptor T) cells are treated by transducing patient's autologous T-lymphocytes in vitro, amplifying suitably and transducing back to the patient's body via autologous transfusion, and no reports on similar designs of CAR-T cells are provided at present.

The invention provides a kit and a method for comprehensively evaluating functions of immune cells in human peripheral blood. The kit for comprehensively evaluating the functions of the immune cells in the human peripheral blood comprises an anti-human CD3, CD4, CD8, CD19, CD21, CD24, CD25, CD27, CD28, CD38, CD56, CD57, CD94, CD127, CD45RA, CXCR3, CXCR5, CCR4, CCR6, CCR7, HLA-DR, PD-1, P30, P46, NKG2D, KIR (NKB1), gamma delta, v delta 2, IgD and IgM antibodies, wherein the antibodies carry fluorescein labels. The kit can be used for comprehensively evaluating the functions of the immune cellsin the human peripheral blood, and is convenient and safe to use.

The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 4 (CCR4) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR4 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.

A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament are required. The present invention can provide a pharmaceutical composition comprising a recombinant antibody against CCR4 and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament.

The invention provides an immune function assessment kit and assessment method for patients with an autoimmune disease. The immune function assessment kit for the patients the autoimmune disease comprises anti-human CD3, CD4, CD8, CD19, CD21, CD24, CD25, CD27, CD28, CD38, CD57, CD127, CD45RA, CXCR3, CXCR5, CCR4, CCR6, CCR7, HLA-DR, PD-1, IgD, and IgM antibodies, and all antibodies referred carry fluorescein labels. The kit can be used for carrying out comprehensive assessment to the function of immune cells of the patients with the autoimmune disease, and usage is convenient and safe.

The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and / or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-β and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII. If this cell is used as a cell therapy in individuals having immune disorders, it is possible to effectively treat immune disorders.

This invention relates to the use of a CCR4 antagonist as an adjuvant, in particular in an immunogenic composition comprising an antigen which elicits an immune response against a pathogen or tumour.

The present disclosure provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and / or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

The invention relates to an application of a CCR4 antagonist in inhibiting cancer growth and metastasis, belongs to the technical field of biological medicines, in particular relates to the CCR4 antagonist, and specially relates to an application of C-021 and ST45177901 in inhibiting cancer growth and metastasis especially liver cancer growth and metastasis. A compound provided by the invention has good clinical application prospects in inhibiting cancer growth and metastasis especially liver cancer growth and metastasis.

The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof.

The invention discloses a vector for editing a nicotiana benthamiana gene based on CRISPR / Cas9 as well as a construction method and application thereof. The vector comprises a BKG-g10 vector and a BKG-g11 vector which are constructed by aiming at a nicotiana benthamiana UbEF1B gene, and / or a BKG-g12 vector and a BKG-g13 vector which are constructed by aiming at a nicotiana benthamiana CCR4 / NOT gene. According to the vector, after the UbEF1B gene or the CCR4 / NOT gene is edited, the growth state of nicotiana benthamiana is normal, and the phenotype is not obviously changed compared with that ofa wild type; and no influence is caused on the character, and progeny continuation is facilitated. Compared with the traditional breeding method, the method for editing a nicotiana benthamiana endogenous gene by virtue of a CRISPR / Cas9 system has the advantage that a disease-resistant material can be obtained more quickly and effectively.

A method of screening a small molecule compound for use in treating rheumatoid arthritis, comprising screening a test compound against a target selected from the group consisting of the gene products encoded by ACHE, ADAMTS16, AGER, BAT3, BRD2, C2, BF, C4A-THRU-TNXB, C6ORF21, LY6G6D, CACNA1D, CCR4, CLIC1, DNM1, EDG1, FAS, HLA-DQB1, HSPA1L, HTR1B, HTR2B, IL15RA, MICA, NEK2, P2RY10, SEC11L1, SIRT2, NFKBIB, SP1, TPH1, VGF, ATF7, DYRK1B, GABRG3, PTPN22, SEMA4G, TAGLN, PCSK7, TEK, or TRPC6, where activity against said target indicates the test compound has potential use in treating rheumatoid arthritis.

A preventive agent, a diagnostic agent or a therapeutic agent for interstitial pneumonia, which comprises an anti-CCR4 antibody and / or an anti-CXCR3 antibody as an active ingredient, a diagnostic agent for discriminating between usual idiopathic interstitial pneumonia and non-specific idiopathic interstitial pneumonia which comprises an anti-CCR4 antibody and an anti-CXCR3 antibody as an active ingredient, and a method for discriminating between usual idiopathic interstitial pneumonia and non-specific idiopathic interstitial pneumonia, which comprises detecting and / or determining a Th2 cell and a Th1 cell in a sample by using an anti-CCR4 antibody and an anti-CXCR3 antibody.

The invention relates to a trisubstituted chiral lactam derivative with the antagonistic effect of a CCR4 shown in a general formula I. The definition of each substituent group in a general formula I is shown as a specification. The invention also relates to a preparation method of a compound shown in the general formula I, a medicament composition containing the compound in the general formula Iand an application of the compound in the general formula I in the preparation of medicaments. The medicaments are used for treating and preventing diseases related to the CCR4.

The invention relates to an application of sorafenib combined with a CCR4 antagonist for restraining cancer growth and transfer, belongs to the technical field of biological medicine and specifically relates to the application of a sorafenib drug and a CCR4 antagonist, especially, combination of C-021 and ST45177901, for restraining the growth and transfer of tumors, such as, liver cancer, kidney cancer, lung cancer, breast cancer, melanin cancer, thyroid cancer and prostate cancer. The compound combined treatment provided by the invention has excellent clinical application prospects in restraining the growth and transfer of the tumors, especially liver cancer, kidney cancer, lung cancer, breast cancer, melanin cancer, thyroid cancer and prostate cancer.